vs
碧迪（BDX）与Stryker Corporation（SYK）财务数据对比。点击上方公司名可切换其他公司
Stryker Corporation的季度营收约是碧迪的1.4倍（$7.2B vs $5.3B），Stryker Corporation净利率更高（11.8% vs 7.3%，领先4.6%），Stryker Corporation同比增速更快（11.4% vs -0.4%），Stryker Corporation自由现金流更多（$1.9B vs $549.0M），过去两年Stryker Corporation的营收复合增速更高（16.9% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
斯特赖克是一款八轮装甲战车，衍生自加拿大LAV III步兵战车，而后者源自瑞士莫瓦格食人鱼系列装甲车。该型战车由加拿大通用动力陆地系统公司为美国陆军生产，制造工厂位于安大略省伦敦市。它默认采用8×4四轮驱动，可切换为8×8全轮驱动模式。
BDX vs SYK — 直观对比
营收规模更大
SYK
是对方的1.4倍
$5.3B
营收增速更快
SYK
高出11.8%
-0.4%
净利率更高
SYK
高出4.6%
7.3%
自由现金流更多
SYK
多$1.3B
$549.0M
两年增速更快
SYK
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $7.2B |
| 净利润 | $382.0M | $849.0M |
| 毛利率 | 45.9% | 64.5% |
| 营业利润率 | 10.5% | 25.2% |
| 净利率 | 7.3% | 11.8% |
| 营收同比 | -0.4% | 11.4% |
| 净利润同比 | 24.0% | 55.5% |
| 每股收益（稀释后） | $1.34 | $2.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXSYK
| Q4 25 | $5.3B | $7.2B | ||
| Q3 25 | $5.9B | $6.1B | ||
| Q2 25 | $5.5B | $6.0B | ||
| Q1 25 | $5.3B | $5.9B | ||
| Q4 24 | $5.2B | $6.4B | ||
| Q3 24 | $5.4B | $5.5B | ||
| Q2 24 | $5.0B | $5.4B | ||
| Q1 24 | $5.0B | $5.2B |
净利润BDXSYK
| Q4 25 | $382.0M | $849.0M | ||
| Q3 25 | $493.0M | $859.0M | ||
| Q2 25 | $574.0M | $884.0M | ||
| Q1 25 | $308.0M | $654.0M | ||
| Q4 24 | $303.0M | $546.0M | ||
| Q3 24 | $400.0M | $834.0M | ||
| Q2 24 | $487.0M | $825.0M | ||
| Q1 24 | $537.0M | $788.0M |
毛利率BDXSYK
| Q4 25 | 45.9% | 64.5% | ||
| Q3 25 | 47.5% | 63.6% | ||
| Q2 25 | 47.8% | 63.8% | ||
| Q1 25 | 42.8% | 63.8% | ||
| Q4 24 | 43.2% | 64.9% | ||
| Q3 24 | 45.7% | 64.0% | ||
| Q2 24 | 46.2% | 63.0% | ||
| Q1 24 | 45.7% | 63.6% |
营业利润率BDXSYK
| Q4 25 | 10.5% | 25.2% | ||
| Q3 25 | 11.8% | 18.7% | ||
| Q2 25 | 16.0% | 18.5% | ||
| Q1 25 | 10.4% | 14.3% | ||
| Q4 24 | 8.8% | 9.0% | ||
| Q3 24 | 11.4% | 19.7% | ||
| Q2 24 | 12.1% | 19.4% | ||
| Q1 24 | 14.5% | 18.5% |
净利率BDXSYK
| Q4 25 | 7.3% | 11.8% | ||
| Q3 25 | 8.4% | 14.2% | ||
| Q2 25 | 10.4% | 14.7% | ||
| Q1 25 | 5.8% | 11.1% | ||
| Q4 24 | 5.9% | 8.5% | ||
| Q3 24 | 7.4% | 15.2% | ||
| Q2 24 | 9.8% | 15.2% | ||
| Q1 24 | 10.6% | 15.0% |
每股收益（稀释后）BDXSYK
| Q4 25 | $1.34 | $2.20 | ||
| Q3 25 | $1.71 | $2.22 | ||
| Q2 25 | $2.00 | $2.29 | ||
| Q1 25 | $1.07 | $1.69 | ||
| Q4 24 | $1.04 | $1.41 | ||
| Q3 24 | $1.37 | $2.16 | ||
| Q2 24 | $1.68 | $2.14 | ||
| Q1 24 | $1.85 | $2.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $4.0B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $25.3B | $22.4B |
| 总资产 | $54.8B | $47.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDXSYK
| Q4 25 | $740.0M | $4.0B | ||
| Q3 25 | $641.0M | $3.3B | ||
| Q2 25 | $735.0M | $2.4B | ||
| Q1 25 | $667.0M | $2.3B | ||
| Q4 24 | $711.0M | $3.7B | ||
| Q3 24 | $1.7B | $3.9B | ||
| Q2 24 | $4.5B | $1.9B | ||
| Q1 24 | $2.3B | $2.3B |
股东权益BDXSYK
| Q4 25 | $25.3B | $22.4B | ||
| Q3 25 | $25.4B | $21.8B | ||
| Q2 25 | $25.5B | $21.2B | ||
| Q1 25 | $25.2B | $20.9B | ||
| Q4 24 | $25.2B | $20.6B | ||
| Q3 24 | $25.9B | $20.1B | ||
| Q2 24 | $25.9B | $19.8B | ||
| Q1 24 | $25.6B | $19.2B |
总资产BDXSYK
| Q4 25 | $54.8B | $47.8B | ||
| Q3 25 | $55.3B | $47.1B | ||
| Q2 25 | $54.9B | $46.3B | ||
| Q1 25 | $54.5B | $46.0B | ||
| Q4 24 | $54.7B | $43.0B | ||
| Q3 24 | $57.3B | $43.8B | ||
| Q2 24 | $55.6B | $39.1B | ||
| Q1 24 | $54.2B | $39.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $2.1B |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $1.9B |
| 自由现金流率自由现金流/营收 | 10.5% | 26.1% |
| 资本支出强度资本支出/营收 | 2.1% | 3.7% |
| 现金转化率经营现金流/净利润 | 1.72× | 2.52× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $4.3B |
8季度趋势，按日历期对齐
经营现金流BDXSYK
| Q4 25 | $657.0M | $2.1B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $164.0M | $250.0M | ||
| Q4 24 | $693.0M | $1.9B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.3B | $633.0M | ||
| Q1 24 | $514.0M | $204.0M |
自由现金流BDXSYK
| Q4 25 | $549.0M | $1.9B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $928.0M | ||
| Q1 25 | $35.0M | $127.0M | ||
| Q4 24 | $588.0M | $1.7B | ||
| Q3 24 | $882.0M | $1.3B | ||
| Q2 24 | $1.1B | $481.0M | ||
| Q1 24 | $380.0M | $37.0M |
自由现金流率BDXSYK
| Q4 25 | 10.5% | 26.1% | ||
| Q3 25 | 17.0% | 22.3% | ||
| Q2 25 | 19.0% | 15.4% | ||
| Q1 25 | 0.7% | 2.2% | ||
| Q4 24 | 11.4% | 25.9% | ||
| Q3 24 | 16.2% | 23.7% | ||
| Q2 24 | 22.4% | 8.9% | ||
| Q1 24 | 7.5% | 0.7% |
资本支出强度BDXSYK
| Q4 25 | 2.1% | 3.7% | ||
| Q3 25 | 6.0% | 3.1% | ||
| Q2 25 | 3.2% | 3.0% | ||
| Q1 25 | 2.4% | 2.1% | ||
| Q4 24 | 2.0% | 4.1% | ||
| Q3 24 | 5.4% | 3.1% | ||
| Q2 24 | 3.6% | 2.8% | ||
| Q1 24 | 2.7% | 3.2% |
现金转化率BDXSYK
| Q4 25 | 1.72× | 2.52× | ||
| Q3 25 | 2.75× | 1.79× | ||
| Q2 25 | 2.12× | 1.26× | ||
| Q1 25 | 0.53× | 0.38× | ||
| Q4 24 | 2.29× | 3.54× | ||
| Q3 24 | 2.94× | 1.77× | ||
| Q2 24 | 2.66× | 0.77× | ||
| Q1 24 | 0.96× | 0.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
SYK
| Medical | $1.3B | 18% |
| Endoscopy | $1.1B | 16% |
| Traumaand Extremities | $1.1B | 15% |
| Instruments | $925.0M | 13% |
| Knees | $749.0M | 10% |
| Neuro Cranial | $669.0M | 9% |
| Neurovascular | $539.0M | 8% |
| Hips | $499.0M | 7% |
| Other Orthopaedics | $267.0M | 4% |
| Spine | $8.0M | 0% |
